Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Testing the Anti-cancer Drug DSP-5336 (Enzomenib) in Prostate Cancer

31. Oktober 2026 aktualisiert von: National Cancer Institute (NCI)

A Phase II Study of Enzomenib in Metastatic Castration-Resistant Prostate Cancer

This phase II trial tests how well enzomenib works in treating patients with prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic) and has continued to grow or spread despite androgen deprivation therapy (castration-resistant). The growth and survival of prostate tumor cells often depends on testosterone. Androgen deprivation therapy blocks the use of testosterone by the tumor cells. Although most tumors respond to androgen deprivation therapy at first, nearly all eventually progress to a castration-resistant state. Enzomenib, a menin inhibitor, targets and blocks menin, a protein that plays a role in the survival and growth of tumor cells.

Studienübersicht

Status

Noch keine Rekrutierung

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

PRIMARY OBJECTIVE:

I. To assess the efficacy of DSP-5336 (enzomenib) as measured by fluorodeoxyglucose (FDG)-positron emission tomography (PET) metabolic response rate, in patients with advanced treatment-refractory prostate cancer.

SECONDARY OBJECTIVES:

I. To determine the safety and tolerability of DSP-5336 (enzomenib) in patients with advanced treatment-refractory prostate cancer.

II. To determine the activity of DSP-5336 (enzomenib) in patients with advanced treatment-refractory prostate cancer.

III To assess the pharmacodynamics of DSP-5336 (enzomenib) in patients with advanced treatment-refractory prostate cancer.

IV. To assess the pharmacokinetics of DSP-5336 (enzomenib) in patients with advanced treatment-refractory prostate cancer.

EXPLORATORY OBJECTIVES:

I. To identify molecular subpopulations associated with response. II. To evaluate circulating tumor deoxyribonucleic acid (DNA) (ctDNA) as a predictor for response.

III. To evaluate differential metabolic responses between prostate-specific membrane antigen (PSMA)-positive and PSMA-negative lesions.

OUTLINE:

Patients continue to receive usual androgen deprivation therapy per standard of care. Patients receive enzomenib orally (PO) twice daily (BID) on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection, FDG PET/computed tomography (CT), PSMA PET/CT, CT, bone scan and tissue biopsy throughout the study.

After completion of study treatment, patients are followed up at 30 days then every 3 months for up to 12 months.

Studientyp

Interventionell

Einschreibung (Geschätzt)

24

Phase

  • Phase 2

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Männlich

Beschreibung

Inclusion Criteria:

  • At the time of informed consent, be ≥ 18 years of age. Because no dosing or adverse event data are currently available on the use of DSP-5336 (enzomenib) in patients < 18 years of age, and because prostate cancer is an adult malignancy, pediatric patients are not part of the target disease population, therefore children are excluded from this study

  • Histologically confirmed prostate adenocarcinoma

  • Metastatic disease documented by conventional imaging, including cross-sectional imaging (CT or magnetic resonance imaging [MRI]) and bone scan. Advanced imaging, including PSMA PET/CT or FDG PET/CT, may be used as supportive documentation but is not sufficient as the sole evidence of metastatic disease for eligibility

  • Patients with treated, stable brain metastases are eligible if neurologically stable for ≥ 4 weeks and not requiring corticosteroids for central nervous system (CNS) disease for at least 7 days prior to registration. Routine screening for asymptomatic CNS metastases is not required

  • Participants with documented progressive metastatic castration-resistant prostate cancer (mCRPC), as assessed by the treating physician based on at least 1 of the following criteria:

    • Prostate specific antigen (PSA) progression may be used for study eligibility, either alone or with radiographic progression. PSA progression is defined as a rise in PSA that is both ≥ 25% and ≥ 2.0 ng/mL above the lowest PSA value since the start of the most recent systemic therapy, or above the pre-treatment baseline PSA if there was no PSA decline. The rise must be confirmed by a second PSA value obtained at least 3 weeks/21 days later. The reference PSA must be ≥ 1.0 ng/mL. Radiographic disease progression in soft tissue based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
    • Radiographic disease progression in bone, defined as appearance of 2 or more new bone lesions on bone scan
  • Participants must have received prior systemic therapy for advanced or metastatic prostate cancer, including both of the following:

    • At least one androgen receptor pathway inhibitor, such as abiraterone, enzalutamide, apalutamide, or darolutamide. Androgen receptor pathway inhibitor (ARPI) exposure in the metastatic castration-sensitive, non-metastatic castration-resistant, or metastatic castration-resistant setting may satisfy this requirement and
    • At least one prior taxane chemotherapy regimen, such as docetaxel or cabazitaxel, and/or PSMA-targeted radioligand therapy. At least one therapy satisfying this second requirement must have been administered in the metastatic castration-resistant setting
  • Prior poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor therapy, immunotherapy, radium-223, or other standard therapies are permitted but are not required to satisfy eligibility

  • Therapy administered solely in the localized, neoadjuvant, adjuvant, or locally advanced setting does not count toward the required prior therapy history. Docetaxel administered solely in the metastatic castration-sensitive setting does not satisfy the required mCRPC therapy criterion

  • Prior orchiectomy or medical castration, with castrate levels of serum testosterone defined as testosterone ≤ 50 ng/dL documented prior to initiation of study treatment. Participants receiving medical castration with a gonadotrophin releasing hormone (GnRH) agonist or antagonist must continue androgen deprivation therapy throughout the treatment phase

  • Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 (Karnofsky ≥ 60%)

  • Absolute neutrophil count ≥ 1,000/mcL

  • Platelets ≥ 75,000/mcL

  • Total bilirubin ≤ 1.5 institutional upper limit of normal (ULN), except in patients with Gilbert syndrome, who may enroll if total bilirubin is ≤ 3 x institutional ULN and direct bilirubin is ≤ 1.5 x institutional ULN

  • Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotranferase (ALT)(serum glutamic pyruvic transaminase [SGPT]) ≤ 3 x institutional ULN

  • Glomerular filtration rate (GFR) ≥ 45 mL/min/1.73 m^2

  • Participants must be willing to undergo baseline and on-treatment tumor biopsies and must have a lesion considered safely accessible for biopsy by the procedural team. Biopsies may be obtained from soft tissue or bone lesions, although soft tissue biopsy is preferred when feasible

  • Ability to understand and the willingness to sign a written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants

  • Patients must have disease evaluable for the primary FDG PET metabolic response endpoint, defined as at least one FDG-avid lesion evaluable on baseline FDG PET/CT. The baseline FDG PET/CT must be performed during screening, and the presence of at least one FDG-avid, evaluable lesion must be confirmed prior to registration. RECIST 1.1 measurable disease is not required for eligibility. Patients with RECIST 1.1 measurable disease will be evaluable for RECIST-based secondary response assessments

  • Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial

  • For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated

  • Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load

  • Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial

  • Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class II or better. Participants must have Fridericia's formula-corrected QT interval (QTcF) ≤ 480 msec based on screening electrocardiogram

  • The effects of DSP-5336 (enzomenib) on the developing human fetus are unknown. For this reason and because menin inhibitors agents are known to be teratogenic, men must agree to use adequate contraception (barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman suspect she is pregnant while her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of DSP-5336 (enzomenib) administration. Participants should not donate sperm for the duration of study participation, and 6 months after completion of the last dose of study drug

Exclusion Criteria:

  • Prior treatment with a menin inhibitor (any investigational compound targeting the menin-MLL complex)
  • Untreated, symptomatic, active, or progressive CNS metastases
  • Inability or unwillingness to undergo FDG and PSMA PET/CT imaging, including inability to lie flat for > 30 minutes. Patients with uncontrolled diabetes mellitus are not eligible if fasting blood glucose cannot be controlled to ≤ 200 mg/dL, or to the institutional threshold required for interpretable FDG PET/CT imaging, despite appropriate medical management
  • Known hypersensitivity to DSP-5336 (enzomenib) or any of its excipients
  • Patients who have received systemic anticancer therapy, including oral anticancer therapy, chemotherapy, radioligand therapy, immunotherapy, targeted therapy, investigational anticancer agents, or other investigational agents, within 5 half-lives or 14 days, whichever is shorter, prior to initiation of study treatment. Longer washout may be required when clinically appropriate based on unresolved toxicity or prolonged expected pharmacodynamic effect. Patients who have received external beam radiation therapy within 2 weeks prior to initiation of study treatment are not eligible. Routine concomitant medications are permitted unless otherwise prohibited by the protocol. Ongoing androgen deprivation therapy with a GnRH agonist or antagonist is permitted
  • Concomitant use of medications known to cause QT prolongation that cannot be safely discontinued or substituted prior to initiation of study treatment
  • Patients with uncontrolled intercurrent illness or any other significant condition(s), including active infection requiring intravenous systemic therapy, that would make participation in this protocol unreasonably hazardous

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: N / A
  • Interventionsmodell: Einzelgruppenzuweisung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Treatment (androgen deprivation therapy, enzomenib)

Patients continue to receive usual androgen deprivation therapy per standard of care. Patients receive enzomenib PO BID on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection, FDG PET/CT, PSMA PET/CT, CT, bone scan and tissue biopsy throughout the study.

Undergo blood sample collection

Andere Namen:
  • Biologische Probensammlung
  • Bioprobe gesammelt
  • Probenentnahme
  • Beispielsammlung

Undergo bone scan

Andere Namen:
  • Knochenszintigraphie

Undergo tissue biopsy

Andere Namen:
  • Bx
  • BIOPSY_TYPE
  • Biopsie

Given FDG

Andere Namen:
  • 18FDG
  • FDG
  • Fludeoxyglucose F 18
  • Fludeoxyglucose (18F)
  • Fludeoxyglucose F18
  • Fluor-18 2-Fluor-2-desoxy-D-Glucose
  • Fluordeoxyglucose F18

Undergo FDG PET/CT

Andere Namen:
  • FDG
  • FDG-PET
  • FDG-PET-Bildgebung

Given usual androgen deprivation therapy

Andere Namen:
  • ADT
  • Androgendeprivationstherapie
  • Anti-Androgen-Therapie
  • Anti-Androgen-Behandlung
  • Antiandrogen-Behandlung
  • Hormonentzugstherapie
  • Androgendeprivationstherapie (ADT)

Undergo CT, FDG PET/CT, and PSMA PET/CT

Andere Namen:
  • CT
  • KATZE
  • Computertomographie
  • Computergestützte axiale Tomographie
  • CT-Scan
  • Tomographie
  • Computerisierte Axialtomographie (Verfahren)
  • Computertomographie (CT)-Scan
  • Diagnosekatze Scan
  • Diagnose -Katzen -Scan -Service -Typ

Given PO

Andere Namen:
  • DSP 5336
  • DSP-5336
  • DSP5336
  • Menin Inhibitor DSP-5336
  • Menin-MLL Interaction Inhibitor DSP-5336

Undergo PSMA PET/CT

Andere Namen:
  • PSMA-PET
  • Prostataspezifisches Membranantigen PET
  • PSMA-Positronen-Emissions-Tomographie

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Fluorodeoxyglucose (FDG) positron emission tomography metabolic response rate
Zeitfenster: Up to 12 months

Will be defined as the proportion of patients achieving a ≥ 30% reduction from baseline in total FDG uptake (standardized uptake value [SUVtotal]) across all FDG-avid lesions. The response rate will be estimated along with its exact 95% confidence interval (CI).

Up to 12 months

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Incidence of adverse events
Zeitfenster: Up to 30 days after last dose of study treatment

Will be graded according to current Cancer Therapy Evaluation Program-required Common Terminology Criteria for Adverse Events version. Will be summarized by type, grade, seriousness, attribution, and relationship to study treatment.

Up to 30 days after last dose of study treatment
Overall response rate
Zeitfenster: Up to 12 months

Will be evaluated using Response Evaluation Criteria in Solid Tumors version 1.1 and Prostate Cancer Working Group 3 (PCWG3). Will be reported with exact 95% CI where applicable. Will be summarized using Kaplan-Meier methods when appropriate.

Up to 12 months
Radiographic progression-free survival (PFS)
Zeitfenster: Up to 12 months

Will be summarized using Kaplan-Meier methods when appropriate.

Up to 12 months
Prostate specific antigen (PSA)-PFS
Zeitfenster: Up to 12 months

Will be summarized using Kaplan-Meier methods when appropriate.

Up to 12 months
Duration of response (DOR)
Zeitfenster: From first documented response to radiographic or clinical progression, or death, assessed up to 12 months

Kaplan-Meier estimates of median DOR and 95% CIs will be provided.

From first documented response to radiographic or clinical progression, or death, assessed up to 12 months
Time to PSA progression
Zeitfenster: From treatment initiation to confirmed PSA progression, will be assessed up to 12 months

Progression will be assessed using PCWG3. Will be summarized using Kaplan-Meier methods.

From treatment initiation to confirmed PSA progression, will be assessed up to 12 months
Overall survival (OS)
Zeitfenster: From treatment initiation to death from any cause, assessed up to 12 months

Will be summarized using Kaplan-Meier estimates, including median OS and 95% CIs.

From treatment initiation to death from any cause, assessed up to 12 months
Tumor response signatures
Zeitfenster: Up to 12 months

Bulk ribonucleic sequencing will be evaluated for transcriptome changes. Will be summarized using Kaplan-Meier methods when appropriate.

Up to 12 months
DSP-5336 (enzomenib) pharmacokinetics (PK)
Zeitfenster: Up to 12 months

PK parameters will be summarized descriptively, and exploratory exposure-safety and exposure-response relationships may be evaluated.

Up to 12 months

Andere Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Tumor signatures
Zeitfenster: Up to 12 months

Mutations identified by whole exome sequencing (WES) will focus on the PI3K/AKT/mTOR pathway and common alterations associated with prostate cancer, lineage plasticity, and therapeutic resistance. Paired baseline and on-treatment tumor samples will be used to assess pharmacodynamic changes in transcriptional programs and AKT pathway signaling. Baseline tumor WES with matched germline deoxyribonucleic acid (DNA) will be used to characterize genomic alterations in the enrolled population.

Up to 12 months
Change in variant allele frequencies of tumor mutations in circulating tumor DNA (ctDNA)
Zeitfenster: At cycle 3 (cycle length = 28 days)

Will be compared to pretreatment. Serial ctDNA dynamics will be explored for association with metabolic response, radiographic response/progression, and clinical outcomes. Given the sample size, correlative analyses will be hypothesis-generating.

At cycle 3 (cycle length = 28 days)
Change in FDG uptake (SUVtotal) in prostate-specific membrane antigen (PSMA)-positive and PSMA-negative lesions
Zeitfenster: Up to 12 months

Exploratory imaging analyses will evaluate metabolic response globally and, when feasible, by lesion phenotype, including PSMA-positive and PSMA-negative lesions. Lesion-level analyses will be descriptive and exploratory, with attention to within-patient heterogeneity.

Up to 12 months

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Ermittler

  • Hauptermittler: Adel Mandl, JHU Sidney Kimmel Comprehensive Cancer Center LAO

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

26. Februar 2027

Primärer Abschluss (Geschätzt)

4. Januar 2029

Studienabschluss (Geschätzt)

4. Januar 2029

Studienanmeldedaten

Zuerst eingereicht

31. Oktober 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

31. Oktober 2026

Zuerst gepostet (Tatsächlich)

4. November 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

4. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

31. Oktober 2026

Zuletzt verifiziert

1. Oktober 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • NCI-2026-07869
  • UM1CA186691 (US NIH Stipendium/Vertrag)
  • NCI-2026-07869 (Registrierungskennung: CTRP (Clinical Trial Reporting Program))
  • 10790 (Andere Kennung: JHU Sidney Kimmel Comprehensive Cancer Center LAO)
  • 10790 (Andere Kennung: CTEP)

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Beschreibung des IPD-Plans

NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Ja

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Produkt, das in den USA hergestellt und aus den USA exportiert wird

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .